北京陽(yáng)光諾和藥物研究股份有限公司是科創(chuàng)板上市企業(yè)（688621），是專注于仿制和創(chuàng)新藥物研究，致力于以技術(shù)服務(wù)為核心，推動(dòng)中國(guó)醫(yī)藥行業(yè)發(fā)展，為客戶提供「臨床前＋臨床+CDMO」全過(guò)程藥物研發(fā)服務(wù)的綜合型CRO公司。陽(yáng)光諾和從藥物發(fā)現(xiàn)、到藥理藥效、藥學(xué)研究，再到臨床研究資源的整合，生物樣本檢測(cè)團(tuán)隊(duì)的構(gòu)建，生產(chǎn)制造能力的整合，成功打造了全過(guò)程CRO服務(wù)模式。

Beijing Sun-novo Pharmaceutical Research Co., Ltd. is a listed company on the Science and Technology Innovation Board (688621). Focusing on generic and innovative drug research, it is a comprehensive CRO company committed to providing technological services, endeavoring to promote China’s pharmaceutical industry. From drug discovery, pharmacological and pharmaceutical research, to the integration of clinical research resources, biological sample testing and manufacturing capabilities, Sun-novo delivers "preclinical+clinical+CDMO" drug R&D services and a whole-process CRO model.

公司主營(yíng)業(yè)務(wù)涵蓋藥理藥效、臨床研究、CDMO、創(chuàng)新藥開(kāi)發(fā)、仿制藥開(kāi)發(fā)及一致性評(píng)價(jià)的綜合研發(fā)服務(wù)，服務(wù)內(nèi)容主要包括藥物發(fā)現(xiàn)、藥理藥效、藥學(xué)研究、臨床研究和生物分析?？蛇M(jìn)行完整的化學(xué)藥研發(fā)、仿制藥一致性評(píng)價(jià)、藥物代謝分析與評(píng)價(jià)研究、多肽藥物研發(fā)、臨床生物等效性試驗(yàn)、藥物Ⅰ-Ⅳ期臨床研究、生物樣品檢測(cè)、注冊(cè)申報(bào)（國(guó)內(nèi)和進(jìn)口）、國(guó)際合作等服務(wù)。

As a one-stop-shop with integrated services and technologies, Sun-novo serves from drug discovery, potency testing, biological analysis, clinical research, to CDMO, innovative drug development, generic drug development and consistency evaluation. It’s also equipped with strong expertise to conduct whole-process chemical drug and peptide drug R&D, generic drug consistency evaluation, metabolism analysis, clinical bioequivalence trials, phase I-IV clinical studies, biological sample testing, as well as drug registration and application (domestic and imported) for international cooperation.